November 9, 2020 -- Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to advance microbiome-based treatments for nonalcoholic steatohepatitis (NASH).
The companies will work together to identify and optimize certain microbiome repertoire associated with the response to Aramchol, Galmed's investigational NASH treatment drug. They will also develop a standalone microbiome-based treatment for NASH and fibrosis as well as to identify specific microbial biomarkers for Aramchol.
The collaboration will utilize MyBiotics' SuperDonor and MyLiveIn solutions to identify and optimize bacteria to reconstitute gut flora in patients with NASH, helping to improve the clinical efficacy and response rate of Aramchol. The MyBiotics microbiome therapeutic technology can increase bacterial diversity, which can be leveraged for product candidates and to produce bacteria more resistant to gastrointestinal conditions.
Copyright © 2020 scienceboard.net